BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25564569)

  • 1. New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.
    Srinivasan R; Ricketts CJ; Sourbier C; Linehan WM
    Clin Cancer Res; 2015 Jan; 21(1):10-7. PubMed ID: 25564569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prospect of precision therapy for renal cell carcinoma.
    Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
    Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
    Ooi A; Dykema K; Ansari A; Petillo D; Snider J; Kahnoski R; Anema J; Craig D; Carpten J; Teh BT; Furge KA
    Cancer Res; 2013 Apr; 73(7):2044-51. PubMed ID: 23365135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
    Su D; Singer EA; Srinivasan R
    Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic alterations in renal cell carcinoma.
    Massari F; Ciccarese C; Santoni M; Brunelli M; Piva F; Modena A; Bimbatti D; Fantinel E; Santini D; Cheng L; Cascinu S; Montironi R; Tortora G
    Cancer Treat Rev; 2015 Nov; 41(9):767-76. PubMed ID: 26169313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
    ; Linehan WM; Spellman PT; Ricketts CJ; Creighton CJ; Fei SS; Davis C; Wheeler DA; Murray BA; Schmidt L; Vocke CD; Peto M; Al Mamun AA; Shinbrot E; Sethi A; Brooks S; Rathmell WK; Brooks AN; Hoadley KA; Robertson AG; Brooks D; Bowlby R; Sadeghi S; Shen H; Weisenberger DJ; Bootwalla M; Baylin SB; Laird PW; Cherniack AD; Saksena G; Haake S; Li J; Liang H; Lu Y; Mills GB; Akbani R; Leiserson MD; Raphael BJ; Anur P; Bottaro D; Albiges L; Barnabas N; Choueiri TK; Czerniak B; Godwin AK; Hakimi AA; Ho TH; Hsieh J; Ittmann M; Kim WY; Krishnan B; Merino MJ; Mills Shaw KR; Reuter VE; Reznik E; Shelley CS; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Tickoo S; Burnett K; Crain D; Gardner J; Lau K; Mallery D; Morris S; Paulauskis JD; Penny RJ; Shelton C; Shelton WT; Sherman M; Thompson E; Yena P; Avedon MT; Bowen J; Gastier-Foster JM; Gerken M; Leraas KM; Lichtenberg TM; Ramirez NC; Santos T; Wise L; Zmuda E; Demchok JA; Felau I; Hutter CM; Sheth M; Sofia HJ; Tarnuzzer R; Wang Z; Yang L; Zenklusen JC; Zhang J; Ayala B; Baboud J; Chudamani S; Liu J; Lolla L; Naresh R; Pihl T; Sun Q; Wan Y; Wu Y; Ally A; Balasundaram M; Balu S; Beroukhim R; Bodenheimer T; Buhay C; Butterfield YS; Carlsen R; Carter SL; Chao H; Chuah E; Clarke A; Covington KR; Dahdouli M; Dewal N; Dhalla N; Doddapaneni HV; Drummond JA; Gabriel SB; Gibbs RA; Guin R; Hale W; Hawes A; Hayes DN; Holt RA; Hoyle AP; Jefferys SR; Jones SJ; Jones CD; Kalra D; Kovar C; Lewis L; Li J; Ma Y; Marra MA; Mayo M; Meng S; Meyerson M; Mieczkowski PA; Moore RA; Morton D; Mose LE; Mungall AJ; Muzny D; Parker JS; Perou CM; Roach J; Schein JE; Schumacher SE; Shi Y; Simons JV; Sipahimalani P; Skelly T; Soloway MG; Sougnez C; Tam A; Tan D; Thiessen N; Veluvolu U; Wang M; Wilkerson MD; Wong T; Wu J; Xi L; Zhou J; Bedford J; Chen F; Fu Y; Gerstein M; Haussler D; Kasaian K; Lai P; Ling S; Radenbaugh A; Van Den Berg D; Weinstein JN; Zhu J; Albert M; Alexopoulou I; Andersen JJ; Auman JT; Bartlett J; Bastacky S; Bergsten J; Blute ML; Boice L; Bollag RJ; Boyd J; Castle E; Chen YB; Cheville JC; Curley E; Davies B; DeVolk A; Dhir R; Dike L; Eckman J; Engel J; Harr J; Hrebinko R; Huang M; Huelsenbeck-Dill L; Iacocca M; Jacobs B; Lobis M; Maranchie JK; McMeekin S; Myers J; Nelson J; Parfitt J; Parwani A; Petrelli N; Rabeno B; Roy S; Salner AL; Slaton J; Stanton M; Thompson RH; Thorne L; Tucker K; Weinberger PM; Winemiller C; Zach LA; Zuna R
    N Engl J Med; 2016 Jan; 374(2):135-45. PubMed ID: 26536169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
    Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
    BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer.
    Yamaguchi Y; Kamai T; Higashi S; Murakami S; Arai K; Shirataki H; Yoshida KI
    BMC Cancer; 2019 Nov; 19(1):1137. PubMed ID: 31752777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.
    Shenoy N; Pagliaro L
    Ann Oncol; 2016 Sep; 27(9):1685-95. PubMed ID: 27329246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas Species.
    Cautain B; de Pedro N; Schulz C; Pascual J; Sousa Tda S; Martin J; Pérez-Victoria I; Asensio F; González I; Bills GF; Reyes F; Genilloud O; Vicente F
    PLoS One; 2015; 10(5):e0125221. PubMed ID: 26018559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on: "Comprehensive molecular characterization of papillary renal-cell carcinoma." Cancer Genome Atlas Research Network.: N Engl J Med. 2016 Jan 14;374(2):135-45.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):578-579. PubMed ID: 28780132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
    Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
    Ooi A; Wong JC; Petillo D; Roossien D; Perrier-Trudova V; Whitten D; Min BW; Tan MH; Zhang Z; Yang XJ; Zhou M; Gardie B; Molinié V; Richard S; Tan PH; Teh BT; Furge KA
    Cancer Cell; 2011 Oct; 20(4):511-23. PubMed ID: 22014576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
    Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.
    Lobo NC; Gedye C; Apostoli AJ; Brown KR; Paterson J; Stickle N; Robinette M; Fleshner N; Hamilton RJ; Kulkarni G; Zlotta A; Evans A; Finelli A; Moffat J; Jewett MA; Ailles L
    BMC Cancer; 2016 Jul; 16():485. PubMed ID: 27422173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.